Sarepta Pauses U.S. Elevidys Shipments Amid FDA Concerns
Originally Published 5 months ago — by CNBC
Sarepta Therapeutics announced it will temporarily pause all shipments of its Elevidys gene therapy in the U.S. following the death of a patient who received a different experimental treatment, after initially refusing to halt shipments despite regulatory requests.